At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 89 enrolled
Drug / intervention
Durvalumab + SoC chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)
In Brief
A Phase 3 clinical trial evaluating Durvalumab + SoC chemotherapy and Placebo + SoC chemotherapy for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 89 participants across 140 sites in 33 countries.
Detailed Summary
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Peru, Poland, Romania, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJul 2020
Primary CompletionAug 2023
TodayJul 2026
First PostedMay 12, 2020
Enrollment StartJul 17, 2020
Primary CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.1 years ago
Interventions
Durvalumab + SoC chemotherapydrug
Experimental Treatment
Placebo + SoC chemotherapyother
Placebo Comparator